Antiviral Drugs Market (By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others; By Type: Branded, Generics; By Application: HIV, Hepatitis, Herpes, Influenza, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20222030

The global antiviral drugs market was valued at US$ 63.8 billion in 2020 and it is expected to be worth around US$ 60.0 billion by 2030.

Report Coverage

Growth Factors

 This is owing to the loss of patent protection of drugs and the high R&D investment required for developing antiviral drugs. However, the rising prevalence of viral infections and the presence of a potential pipeline for the treatment of HIV infection are expected to fuel the growth over the forecast period.

The increasing prevalence of influenza with other complications such as viral pneumonia, obesity, and the rising geriatric population drives the market growth. Moreover, pneumonia is one of the major causes of death in children worldwide. According to the WHO, Pneumonia causes 808,694 children’s deaths in 2017, accounting for 15.0% of all deaths of children under 5 years old. It is most prevalent in South Asia and the sub-Saharan African region.

Antiviral Drugs Market Trends

The COVID-19 pandemic has boosted antiviral medicine sales. The market is growing due to a sudden rise in the number of COVID-19 cases and the primary focus of medical facilities on the treatment of COVID-19 patients. Furthermore, several pharmaceutical companies are focusing on new drug development in order to provide more effective treatment and better patient results. For instance, Cipla Inc. teamed with Gilead Sciences in May 2020 to manufacture and distribute remdesivir to treat COVID-19 patients in over 127 countries. As a result, aggressive collaborations and strategic efforts by market competitors to widen their antiviral medication manufacturing capacities in order to serve a large patient base have fueled the global market share.

The global anti-viral medications market share is being pushed by an increase in the reported rate of viral disorders. Furthermore, an increase in R&D activities and the expansion of more recent and updated details, like vaccinations and combined therapy, are expected to drive the antiviral drug market.

The production of a safe, efficient, and targeted antiviral from the structure to the ground requires time and limits the market revenue and profit. Potential viral pandemics emphasize the need for broad-spectrum antiviral medications, such as direct-acting antivirals, that can be rapidly deployed on a large scale to prevent viral spread until adequate vaccines are developed. Increasing infection prevention methods and vaccination accessibility knowledge is also expected to restrict the market of antiviral drugs.

Increased partnerships for antiviral drug development and manufacturing are expected to result in the development of several innovative drugs in the forecast period. The leading competitors in the market are collaborating on the research and development of innovative treatments to reduce the strain of virus antiviral drugs. For instance, In December 2021, Cipla Limited announced the acquisition of approximately 33% of an equity stake in Clean Max Auriga Power Limited Liability Partnership. The agreement is aligned with the business' goal to grow the use of renewable resources in its activities and to achieve the legal standards for just being a captive user under power generation regulations.

Drug Class Insights

The reverse transcriptase inhibitors segment dominated the market for antiviral drugs and accounted for the largest revenue share of 50% in 2021. The segment is anticipated to maintain its dominance over the forecast period. The high share of reverse transcriptase inhibitors can be attributed to the increasing diagnosis and treatment rate of HIV, as these medicines are mainly used to treat HIV infection and the high effectiveness of these drugs against viral infections. Moreover, the presence of reverse transcriptase inhibitors in the pipeline will fuel the demand for these drugs in the coming years. The drug class includes Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs).

The protease inhibitors segment held the second-largest revenue share in 2020 and is anticipated to witness a CAGR of -1.4% over the forecast period. The decline in the segment growth can be attributed to increasing vaccination against viral infections and reduced R&D activities in the development of protease inhibitors.

Type Insights

The branded segment dominated the market and accounted for the largest revenue share of 57.2% in 2020. The segment is expected to maintain its dominance over the forecast period. Branded antiviral medicines such as Biktarvy, Genvoya, Triumeq, Mavyret, and Prezista hold a significant share of the market. The high adoption rate of branded drugs in the North American and European markets and the high cost of drugs are expected to drive the segment.

Increasing demand for the generic version of antiviral drugs in developing countries due to its cost-effectiveness is driving the generics segment. The generic antiviral drugs segment is highly competitive and price-sensitive. The presence of a large number of generic pharmaceutical manufacturers such as Cipla Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Mylan, and others make the market highly competitive for generic antiviral drugs.

Application Insights

The HIV segment dominated the market and held the largest revenue share of 45% in 2021. The segment is expected to witness the fastest growth rate over the forecast period. The high prevalence of HIV infection coupled with a high treatment rate, presence of branded drugs, and government initiatives to increase the treatment rate is estimated to drive the market at a higher growth rate. For instance, in 2019, the U.S. government announced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2030. The initiative seeks to reduce HIV infections and improve the diagnosis and treatment rate in the U.S. Moreover, the presence of strong pipeline drugs for HIV infection will also fuel market growth over the forecast period.

The hepatitis segment held the second-largest revenue share in 2021. Increasing vaccination against hepatitis A and B is affecting the growth adversely. Moreover, the outbreak of the COVID-19 pandemic has significantly increased the growth of the others segment in 2020. Due to COVID-19, the others segment share increased from 6.3% to 23.5% from 2019 to 2020.

Regional Insights

North America dominated the market and accounted for the largest revenue share in 2021.The market decline can be attributed to the loss of market exclusivity of branded drugs, increasing vaccination rate against viral infections, and government initiatives to reduce the incidence of viral infections. For instance, the U.S. government is undertaking various measures including investment in infectious diseases programs and promoting the R&D activities of innovative therapies to manage viral infections.

In Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate during the forecast period. The high growth of the market can be attributed to the increasing prevalence and treatment rate of viral infections, developing healthcare infrastructure in the region, and increasing awareness among people regarding infectious diseases. Moreover, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the increasing geriatric population in the region are some of the key factors driving the segment growth.Key Players

• F. Hoffmann-La Roche Ltd.

• GlaxoSmithKline plc

• AbbVie

• Merck & Co., Inc.

• Johnson & Johnson Services, Inc.

• Bristol-Myers Squibb Company

• Cipla Inc.

• Aurobindo Pharma

• Dr. Reddy’s Laboratories Ltd. 

Market Segmentation

• Drug Class

  • DNA Polymerase Inhibitors

  • Reverse Transcriptase Inhibitors

  • Protease Inhibitors

  • Neuraminidase Inhibitors

  • Others

• Type

  • Branded

  • Generics

• Application

  • HIV

  • Hepatitis

  • Herpes

  • Influenza

  • Others

• Regional

  • North America

    • U.S

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • India

    • China

    • Japan

    • Australia

    • South Korea

  • Latin America

    • Argentina

    • Brazil

    • Mexico

    • Colombia

  • Middle East & Africa

    • Saudi Arabia

    • UAE

    • South Africa

The Antiviral Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report provides size (in terms of volume and value) of Antiviral Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

This report focuses on the global Antiviral Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Antiviral Drugs market development in United States, Europe and China.

It is pertinent to consider that in a volatile global economy, we haven’t just conducted Antiviral Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

In terms of production side, this report researches the Antiviral Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.

In terms of consumption side, this report focuses on the consumption of Antiviral Drugs by regions (countries) and application.

Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Antiviral Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.

With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Antiviral Drugs market companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Antiviral Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.

Overall, this is an in-depth research report specifically for the Antiviral Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.

Antiviral Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Antiviral Drugs market.

Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Antiviral Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.

Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Antiviral Drugs market. These factors have benefited the growth of the global market for Antiviral Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.

New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Antiviral Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).

In this study, the years considered to estimate the market size of Antiviral Drugs are as follows:

• History Year: 2017-2020

• Base Year: 2021

• Forecast Year 2021 to 2030

Reasons to Purchase this Report:

- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Market Size Estimation

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).

The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.

Secondary Sources

Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.

The study objectives of this report are:

• To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
• Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
• Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
• To define, describe and forecast the market by type, application and region.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.